Opko Health Inc. (NASDAQ:OPK) has been given an average recommendation of “Buy” by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $9.50.
OPK has been the topic of several analyst reports. Barrington Research reaffirmed a “buy” rating and issued a $7.00 price target on shares of Opko Health in a report on Friday, October 5th. BidaskClub lowered shares of Opko Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a report on Friday, November 30th. Finally, ValuEngine raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Friday, September 7th.
NASDAQ:OPK traded up $0.03 during trading hours on Monday, reaching $3.28. The company’s stock had a trading volume of 4,572,311 shares, compared to its average volume of 4,052,550. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -11.31 and a beta of 1.90. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.40. The company has a quick ratio of 0.78, a current ratio of 0.91 and a debt-to-equity ratio of 0.03.
Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.03. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. The business had revenue of $250.00 million for the quarter, compared to analyst estimates of $264.04 million. During the same period in the previous year, the company earned ($0.08) earnings per share. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. On average, sell-side analysts expect that Opko Health will post -0.21 EPS for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Opko Health by 2.1% during the third quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after buying an additional 614,442 shares during the last quarter. Teachers Advisors LLC grew its holdings in shares of Opko Health by 3.5% during the third quarter. Teachers Advisors LLC now owns 754,427 shares of the biotechnology company’s stock valued at $2,610,000 after buying an additional 25,222 shares during the last quarter. MetLife Investment Advisors LLC grew its holdings in shares of Opko Health by 38.2% during the third quarter. MetLife Investment Advisors LLC now owns 207,467 shares of the biotechnology company’s stock valued at $718,000 after buying an additional 57,299 shares during the last quarter. Pacer Advisors Inc. purchased a new stake in shares of Opko Health during the third quarter valued at $198,000. Finally, BlueMountain Capital Management LLC purchased a new stake in shares of Opko Health during the third quarter valued at $187,000. 26.20% of the stock is currently owned by hedge funds and other institutional investors.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Featured Story: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.